EGFR and glioblastoma: A phase I clinical trial evaluated intrathecal administration of dual-target CAR-T cells directed against two glioblastoma-associated antigens: epidermal growth factor receptor (EGFR) and interleukin 13 receptor α2 (IL13Rα2).